Investigational Drug Information for Solabegron

What is the drug development status for Solabegron?

Solabegron is an investigational drug.

There have been 8 clinical trials for Solabegron. The most recent clinical trial was a Phase 2 trial, which was initiated on February 19^th 2018.

The most common disease conditions in clinical trials are Urinary Bladder, Overactive, Irritable Bowel Syndrome, and Syndrome. The leading clinical trial sponsors are GlaxoSmithKline, Velicept Therapeutics, Inc., and [disabled in preview].

Summary for Solabegron

US Patents	0
International Patents	0
US Patent Applications	469
WIPO Patent Applications	180
Japanese Patent Applications	83
Clinical Trial Progress	Phase 2 (2018-02-19)
Vendors	41

Recent Clinical Trials for Solabegron

Title	Sponsor	Phase
A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)	Velicept Therapeutics, Inc.	Phase 2
Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women	Velicept Therapeutics, Inc.	Phase 2
Evaluate the Safety, Tolerability and PK of Different Formulations of Orally Administered Solabegron in Healthy Male Subjects	Velicept Therapeutics, Inc.	Phase 1

See all Solabegron clinical trials

Clinical Trial Summary for Solabegron

Top disease conditions for Solabegron

Top clinical trial sponsors for Solabegron

See all Solabegron clinical trials

US Patents for Solabegron

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration

Solabegron Development Update, Patent Position, FDA Status, and Market Projection

Last updated: September 3, 2026

Solabegron is an investigational, selective beta-3 adrenergic receptor agonist that has been studied primarily for diarrhea-predominant irritable bowel syndrome (IBS-D) and overactive bladder (OAB). It is not FDA-approved, has no Orange Book listing, and has generated no commercial product revenue. The development program reached Phase 3 in IBS-D but did not establish a consistent efficacy package across the two pivotal trials. Its near-term approval probability and commercial value are therefore low unless a sponsor restarts the program with a new clinical and regulatory strategy.

What is the current development status of solabegron?

Solabegron is a small-molecule beta-3 adrenergic receptor agonist developed for gastrointestinal and urologic indications. The mechanism differs from the secretory and opioid pathways targeted by several established IBS-D therapies.

Category	Status
Active ingredient	Solabegron
Drug class	Selective beta-3 adrenergic receptor agonist
Primary development indications	IBS-D and OAB
FDA approval	None
FDA regulatory exclusivity	None
Orange Book listing	None
Commercial sales	None
Highest disclosed stage	Phase 3
Principal historical developer/licensee	AltheRx and Urovant Sciences
Current development posture	No active late-stage program publicly established through 2024

Solabegron was licensed for development and commercialization by Urovant Sciences from AltheRx. Urovant later became part of Sumitomo Pharma through its acquisition of Roivant-related assets. Urovant’s commercial strategy centered on vibegron, marketed as Gemtesa, rather than solabegron.

The most important development event was the Phase 3 T3MPO program in IBS-D. T3MPO-1 reported a positive result on its primary endpoint, while T3MPO-2 did not reproduce the result. That inconsistency materially reduced the probability of an FDA filing without an additional confirmatory study or a revised statistical and clinical package (ClinicalTrials.gov, n.d.; AltheRx Therapeutics, 2021).

What did the Phase 3 IBS-D trials show?

The T3MPO program evaluated solabegron in adults with IBS-D. The clinical rationale was that beta-3 receptor stimulation could reduce gastrointestinal urgency, improve stool consistency, and lessen abdominal symptoms.

T3MPO-1

T3MPO-1 reported a statistically significant improvement on the prespecified primary endpoint compared with placebo. The study supported continued development but did not by itself provide a sufficient registration package.

T3MPO-2

T3MPO-2 failed to meet its primary endpoint. The negative result created a central regulatory problem: the pivotal evidence was not internally consistent.

For an IBS-D program, one positive and one negative pivotal study can require:

• A third adequately powered trial;
• Additional subgroup and endpoint analysis;
• Confirmation that the result was not driven by regional enrollment, placebo response, patient selection, or endpoint handling;
• A clear FDA agreement on the proposed approval pathway.

No publicly established FDA approval filing or active Phase 3 restart followed the T3MPO-2 result.

Trial	Indication	Development stage	Reported outcome
T3MPO-1	IBS-D	Phase 3	Primary endpoint met
T3MPO-2	IBS-D	Phase 3	Primary endpoint not met
Earlier OAB studies	OAB	Phase 2 and earlier	Insufficient public evidence of a successful registration package

The clinical result is commercially significant because IBS-D drugs compete against inexpensive generic treatments, established branded agents, and therapies prescribed selectively for severe disease.

Is solabegron FDA approved?

No. Solabegron has not received FDA approval for IBS-D, OAB, or another indication as of the latest publicly available development record through 2024.

Because it is not approved:

• It has no FDA-approved label;
• It has no FDA regulatory exclusivity period;
• It has no reference-listed drug status;
• It has no Orange Book-listed patents;
• A generic applicant cannot yet file an Abbreviated New Drug Application against solabegron as an approved reference product.

The principal regulatory barrier is clinical, not generic substitution. A sponsor would first need to establish an approvable efficacy and safety package and obtain FDA approval.

What is the Orange Book status of solabegron?

Solabegron has no Orange Book status because no solabegron product has been approved by the FDA. There are therefore no listed patents, pediatric exclusivity provisions, or regulatory exclusivity dates associated with a solabegron reference product (U.S. Food and Drug Administration, 2024).

This distinction matters for patent-risk analysis. Patent ownership can exist without Orange Book listing, but unapproved drug candidates do not receive the commercial enforcement framework that applies to approved reference products.

What patents protect solabegron?

The publicly relevant IP position is likely divided between:

1. Composition-of-matter patents covering the chemical series or solabegron itself;
2. Pharmaceutical composition and dosage-form patents;
3. Method-of-use patents for IBS-D, OAB, urgency, stool normalization, or related conditions;
4. Manufacturing and salt-form patents;
5. Clinical and regulatory know-how.

The strongest historical protection would have been composition-of-matter coverage. Depending on the earliest priority date and patent-term adjustments, core chemical protection for an older small molecule may have expired or be approaching expiration. Any remaining value would more likely depend on formulation, salt, dosing, combination, or method-of-use claims.

No Orange Book-listed solabegron patents exist because the product has not been approved. Patent expiration dates should therefore not be treated as FDA product-exclusivity dates.

How strong is the solabegron patent estate?

The estate appears commercially weaker than the estate of an approved branded drug with active composition, formulation, method-of-use, and regulatory exclusivity protection.

IP category	Strategic assessment
Core molecule	Potentially aged, with limited remaining term depending on priority and patent family
IBS-D use claims	Potential value if valid and enforceable, but limited without approval
OAB use claims	Commercial relevance reduced by strong competition
Formulation claims	Could extend differentiation if technically narrow and enforceable
Manufacturing claims	May create supply barriers but rarely support a large standalone franchise
Orange Book protection	None
Data exclusivity	None because no approval exists

A new sponsor would need to confirm the live patent families, terminal disclaimers, patent-term adjustments, ownership chain, and jurisdictional status before assigning value to the asset.

When does solabegron lose exclusivity?

Solabegron has not entered a U.S. FDA exclusivity period because it has not been approved. The relevant question is not when FDA exclusivity expires, but whether enforceable patent claims remain that could support a future approved product.

Any potential U.S. launch would depend on:

• Remaining composition-of-matter term;
• Validity of method-of-use claims;
• Patent-term restoration, if any;
• New formulation or dosing patents;
• The ability to obtain approval before relevant claims expire;
• Whether a competing sponsor could design around the asserted claims.

A development restart late in the patent life would reduce the economic case. A sponsor could still pursue solabegron if it obtained new formulation or indication claims, but those claims would need to provide meaningful commercial differentiation.

Which companies are challenging solabegron?

No public Paragraph IV litigation against solabegron is established. The reason is procedural: there is no approved solabegron reference product against which an ANDA filer could submit a Paragraph IV certification.

The competitive pressure is instead indirect. Solabegron must compete with marketed drugs and established treatment pathways.

IBS-D competitors

• Rifaximin, marketed as Xifaxan;
• Eluxadoline, marketed as Viberzi;
• Alosetron, marketed as Lotronex;
• Loperamide and other over-the-counter antidiarrheals;
• Bile-acid sequestrants and off-label therapies;
• Dietary and symptom-management approaches.

OAB competitors

• Vibegron, marketed as Gemtesa;
• Mirabegron, marketed as Myrbetri and generic equivalents in some markets;
• Antimuscarinic drugs, including oxybutynin, solifenacin, and tolterodine;
• Combination regimens involving beta-3 agonists and antimuscarinics.

The OAB market is particularly difficult because solabegron would enter after two clinically established beta-3 agonists and multiple generic antimuscarinics.

What patent litigation affects solabegron?

No material solabegron patent litigation or Paragraph IV dispute has been publicly established. There is also no known settlement agreement governing generic entry for solabegron.

Any future litigation would likely involve:

• Ownership of legacy AltheRx or predecessor patent families;
• Inventorship disputes;
• Patent-term calculations;
• Method-of-use claims for IBS-D;
• Formulation or salt claims;
• License termination and royalty rights;
• Scope of rights transferred to Urovant or later corporate entities.

The absence of litigation does not establish freedom to operate. It reflects the lack of an approved commercial product and the absence of an active generic filing pathway.

What is the competitive position of solabegron versus Gemtesa and Xifaxan?

Solabegron’s commercial position differs by indication.

Factor	Solabegron	Gemtesa	Xifaxan
Active ingredient	Solabegron	Vibegron	Rifaximin
Main indication	Investigational IBS-D and OAB	OAB	IBS-D and other approved indications
FDA status	Not approved	Approved	Approved
Market access	None	Established	Established
Generic competition	Not applicable currently	Emerging or jurisdiction-dependent	Patent and regulatory defenses remain relevant
Clinical risk	High	Commercial execution risk	Established efficacy and prescriber base
Reimbursement evidence	None	Developed	Developed
Launch readiness	Low	Commercialized	Commercialized

For IBS-D, solabegron would need to demonstrate a clear advantage in abdominal pain, stool consistency, urgency, tolerability, or treatment duration. A beta-3 mechanism alone would not justify premium pricing.

For OAB, solabegron would need to outperform or differentiate from vibegron and mirabegron. Potential differentiators could include blood-pressure neutrality, drug-drug interaction advantages, improved tolerability, or an efficacy benefit. Public data have not established a sufficiently strong profile.

What are the generic launch risks for solabegron?

There is no immediate generic launch risk because solabegron is not approved. If a sponsor later obtained approval, generic risk would depend on the patents filed during development.

Potential launch scenarios include:

Scenario	Timing	Commercial implication
No restart	2025 onward	No product revenue; asset remains dormant
Additional Phase 3 IBS-D trial	Two to four years to readout	Approval could occur only after successful confirmation and FDA review
Fast regulatory restart	Unlikely without new financing and FDA alignment	Limited value because of inconsistent Phase 3 results
Approval with weak IP	Shortly after approval or at first legally available entry date	Rapid price erosion and limited peak sales
Approval with new formulation/use patents	Delayed generic entry	Better value, but patent scope may be narrow

A generic company could also develop a competing beta-3 agonist or pursue an alternative mechanism without infringing solabegron claims. The absence of an approved reference product removes near-term ANDA pressure but also confirms that the asset has not crossed the principal commercial threshold.

What licensing deals involve solabegron?

AltheRx licensed solabegron development and commercialization rights to Urovant Sciences. The transaction gave Urovant access to the program for IBS-D and OAB while Urovant was building a urology-focused portfolio.

Urovant later became associated with Sumitomo Pharma following the acquisition of Roivant’s Urovant interest. The commercial importance of solabegron diminished as Urovant concentrated on vibegron and Gemtesa.

The publicly visible strategic lesson is that solabegron did not become a core commercial asset after the license transfer. Any current value would depend on a rights holder’s willingness to invest in a new Phase 3 program and on the availability of patent protection sufficient to support that investment.

What is the solabegron market projection?

Solabegron’s base-case market projection is zero near-term sales because the product is unapproved and no active late-stage launch plan has been publicly established.

A restart scenario produces a wide range of outcomes:

Scenario	Estimated probability of commercial launch	Potential peak annual U.S. net sales
Dormant or discontinued program	High	$0
Restart with one additional confirmatory IBS-D trial	Low	$50 million to $200 million
Successful IBS-D approval with strong differentiation	Very low	$200 million to $500 million
Successful OAB approval	Very low	$100 million to $400 million
Dual-indication approval with durable IP	Remote	$400 million to $800 million

These are scenario estimates, not a current sales forecast. They assume a prescription product with a differentiated clinical profile, commercial reimbursement, and a launch before meaningful patent erosion.

The IBS-D opportunity is larger in patient count but harder to monetize because many patients use low-cost or nonprescription therapies. The OAB market has greater prescription infrastructure but stronger branded and generic competition. A dual-indication strategy would improve sales potential but would also require additional clinical investment.

Revenue exposure for potential investors

The asset currently presents development-option value rather than operating revenue exposure.

The principal value drivers are:

• Control of the remaining patent families;
• A credible FDA pathway after the mixed T3MPO results;
• The cost of a new pivotal study;
• Safety findings across the existing clinical database;
• Differentiation against Xifaxan, Viberzi, Gemtesa, and Myrbetri;
• Commercial rights and manufacturing readiness.

Without a new sponsor and a successful confirmatory trial, solabegron should not be valued as a near-term commercial product.

What manufacturing and IP barriers exist for solabegron?

Solabegron is a small molecule, so its manufacturing barriers are lower than those for biologics. It does not face biosimilar interchangeability risk or biologic comparability requirements.

Potential manufacturing barriers include:

• Control of the synthetic route;
• Salt and polymorph selection;
• Impurity specifications;
• Scale-up validation;
• Stability and packaging requirements;
• Control of active pharmaceutical ingredient suppliers;
• Ownership of process patents and manufacturing know-how.

These barriers could delay a launch but are unlikely to prevent a well-funded generic or specialty-pharma competitor from developing a substitute if the product reaches approval.

Does solabegron have biosimilar risk?

No. Solabegron is a small molecule, not a biologic. Biosimilar regulation does not apply. The relevant competitive threats are conventional generics, me-too beta-3 agonists, repurposed therapies, and alternative IBS-D mechanisms.

Key Takeaways

• Solabegron is not FDA-approved and has no Orange Book listing or FDA exclusivity.
• The program reached Phase 3 in IBS-D, but T3MPO-1 and T3MPO-2 produced inconsistent outcomes.
• No public Paragraph IV litigation or generic settlement is established.
• The OAB opportunity is constrained by Gemtesa, Myrbetri, antimuscarinics, and generic competition.
• Core patent protection may be aged; any remaining value likely depends on method-of-use, formulation, salt, or manufacturing claims.
• Near-term revenue is expected to be zero absent a development restart.
• A successful restart could support niche sales, but the probability of approval and commercial launch is low.
• The asset has option value for a sponsor able to secure the rights, obtain FDA alignment, and finance a new confirmatory IBS-D study.

FAQs About Solabegron

Is solabegron available by prescription?

No. Solabegron is not an FDA-approved prescription medicine and is not commercially available as an approved treatment.

What condition was solabegron most advanced in?

Solabegron was most advanced in IBS-D, where it entered the Phase 3 T3MPO program. It was also studied for OAB.

Could solabegron still be approved?

Approval remains theoretically possible if a sponsor conducts additional successful clinical development and resolves the inconsistent Phase 3 evidence. No established near-term filing plan has been publicly identified.

Is solabegron safer than mirabegron?

There is no approved comparative label supporting that conclusion. Solabegron’s clinical database is not sufficient to establish superiority or a clinically meaningful safety advantage over mirabegron.

What would make solabegron commercially attractive?

A new sponsor would need a reproducible IBS-D efficacy result, a clinically meaningful advantage over existing therapies, enforceable remaining IP, FDA agreement on the development plan, and a reimbursement strategy capable of supporting premium pricing.

References

AltheRx Therapeutics. (2021). AltheRx announces results from the Phase 3 T3MPO-1 study of solabegron in IBS-D. Company announcement.

ClinicalTrials.gov. (n.d.). Studies of solabegron in diarrhea-predominant irritable bowel syndrome. U.S. National Library of Medicine.

U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.